EAST HANOVER, N.J., April 11 /PRNewswire/ -- New data show that a once-yearly infusion of Reclast(R) (zoledronic acid) Injection 5mg was significantly better than risedronate at increasing bone mass ...

Reclast (zoledronic acid) is a medication that the Food and Drug Administration (FDA) has approved for preventing and treating osteoporosis in females after menopause, males, and individuals who take ...

Medicare covers the injectable drug, Reclast, when a doctor deems it medically necessary for the treatment and prevention of osteoporosis. There are specific eligibility criteria, including having ...

A new drug called Reclast may make it possible to reduce osteoporosis fractures with a single annual infusion that takes 15 minutes. Reclast's maker, Novartis, is preparing to submit Reclast for FDA ...

The FDA has approved Reclast (zoledronic acid injection, from Novartis) for the prevention of new clinical fractures in patients who have recently had a low-trauma hip fracture. The approval was based ...

Please provide your email address to receive an email when new articles are posted on . Individuals undergoing treatment for cancer are known to be at greater risk for bone loss, subsequent ...

The FDA has approved once-yearly Reclast (zoledronic acid, from Novartis) injection, a bisphosphonate, for the treatment and prevention of osteoporosis caused by glucocorticoids for patients expected ...

TEL AVIV (MarketWatch) -- Novartis, the Basel drugmaker, said that the first clinical study of osteoporosis patients who have fractured a hip showed that its Reclast once-yearly injection "reduced the ...

EAST HANOVER, N.J., Oct. 16 Novartis announced today that new six-year data reinforce the long-term efficacy and safety profile of once-yearly Reclast® (zoledronic acid) injection in postmenopausal ...

You are able to gift 5 more articles this month. Anyone can access the link you share with no account required. Learn more. DEAR DR. ROACH: For the last few years, I have been taking yearly Reclast ...

Reclast (zoledronic acid or zoledronate) is approved by the Food and Drug Administration (FDA) to treat and prevent osteoporosis in males, females after menopause, and people taking glucocorticoids.